Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy"

被引:0
|
作者
Lin, Hollis [1 ]
Agarwal, Sonalee [1 ]
Betts, Marissa [2 ]
Fahrbach, Kyle [2 ]
Chitnis, Madhura [2 ]
Polydefkis, Michael [3 ]
机构
[1] Alnylam Pharmaceut, Cambridge, MA USA
[2] Evidera, Waltham, MA USA
[3] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA
关键词
Transthyretin amyloid polyneuropathy; indirect treatment comparison;
D O I
10.1080/14656566.2019.1620987
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:1529 / 1530
页数:2
相关论文
共 50 条
  • [1] An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Plante-Bordeneuve, Violaine
    Lin, Hollis
    Gollob, Jared
    Agarwal, Sonalee
    Betts, Marissa
    Fahrbach, Kyle
    Chitnis, Madhura
    Polydefkis, Michael
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (04) : 473 - 481
  • [2] Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy"
    Salvo, E. M.
    Samjoo, I. A.
    Tran, D.
    Cameron, C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (12) : 1527 - 1528
  • [3] Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gorevic, Peter
    Franklin, Jaclyn
    Chen, Jihong
    Sajeev, Gautam
    Wang, Jessie C. H.
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (01) : 121 - 129
  • [4] Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Merkel, Madeline
    Danese, David
    Chen, Chongshu
    Wang, Jessie
    Wu, Aozhou
    Yang, Hongbo
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1205 - 1214
  • [5] Indirect comparison of patisiran and tafamidis for treatment of hereditary transthyretin- mediated (hATTR) amyloidosis with polyneuropathy
    Coelho, Teresa
    Polydefkis, Michael
    Lin, Hollis
    Gollob, Jared
    Agarwal, Sonalee
    Betts, Marissa
    Fahrbach, Kyle
    Chitnis, Madhura
    Plante-Bordeneuve, Violaine
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 254 - 255
  • [6] Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Labeyrie, Celine
    Merkel, Madeline
    Sethi, Sakshi
    Popadic, Lyuba
    Yang, Hongbo
    Sweetser, Marianne T.
    Lin, Hollis
    Adams, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
  • [7] Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) : 95 - 99
  • [8] Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy
    Mueschen, Lars H.
    Koerner, Gudrun
    Gingele, Stefan
    Haenselmann, Anja
    Bavendiek, Udo
    Skripuletz, Thomas
    MUSCLE & NERVE, 2021, 64 (03) : E11 - E13
  • [9] SIMULATED TREATMENT COMPARISON AND MATCHINGADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF EPLONTERSEN AND VUTRISIRAN FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Karam, C.
    Gillmore, J. D.
    Chen, G.
    Jenkins, N. C.
    Hale, M. J.
    Chen, J.
    Viney, N. J.
    Schneider, E.
    VALUE IN HEALTH, 2023, 26 (12) : S46 - S47
  • [10] Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
    Schmidt, Hartmut H.
    Wixner, Jonas
    Plante-Bordeneuve, Violaine
    Munoz-Beamud, Francisco
    Llado, Laura
    Gillmore, Julian D.
    Mazzeo, Anna
    Li, Xingyu
    Arum, Seth
    Jay, Patrick Y.
    Adams, David
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (06) : 1646 - 1657